a 2017

The Cost Study of Cetuximab and Panitumumab in The First-Line Treatment of Mcrc in The Czech Republic

HRADECKÁ, Irena, Barbora ŘÍHOVÁ and Regina DEMLOVÁ

Basic information

Original name

The Cost Study of Cetuximab and Panitumumab in The First-Line Treatment of Mcrc in The Czech Republic

Authors

HRADECKÁ, Irena (203 Czech Republic, belonging to the institution), Barbora ŘÍHOVÁ (203 Czech Republic, guarantor, belonging to the institution) and Regina DEMLOVÁ (203 Czech Republic)

Edition

2017

Other information

Language

English

Type of outcome

Konferenční abstrakt

Field of Study

30200 3.2 Clinical medicine

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 5.494

RIV identification code

RIV/00216224:14110/17:00098995

Organization unit

Faculty of Medicine

ISSN

UT WoS

000413599900143

Keywords in English

Cetuximab; Panitumumab

Tags

Tags

International impact, Reviewed
Změněno: 16/3/2018 18:16, Soňa Böhmová

Abstract

V originále

Meeting abstract The Cost Study of Cetuximab and Panitumumab in The First-Line Treatment of Mcrc in The Czech Republic.